Seven target genes of dehydrovomifoliol in NAFLD treatment were screened out, namely E2F1, MERTK, SOX17, MMP9, SULT2A1, VEGFA, and BLVRA. This evidence concerns the gene MERTK and metabolic dysfunction-associated steatotic liver disease.